Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

New Programs, Product Launches, Corporate Announcements and Financial Results - Research Report on Aetna, Illumina,



New Programs, Product Launches, Corporate Announcements and Financial Results
 - Research Report on Aetna, Illumina, Pharmacyclics, WellCare, and BioCryst

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, August 27, 2013

NEW YORK, August 27, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Aetna Inc.
(NYSE: AET), Illumina Inc. (NASDAQ: ILMN), Pharmacyclics Inc. (NASDAQ: PCYC),
WellCare Health Plans, Inc. (NYSE: WCG), and BioCryst Pharmaceuticals Inc.
(NASDAQ: BCRX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Aetna Inc. Research Report

On August 20, 2013, Aetna Inc. (Aetna) announced a new pilot program called
the Aetna Rx Home Success Program^SM. According to the Company, the program
works in association with CVS Caremark pharmacists and Dovetail Health to
support Aetna members who are taking multiple medications to manage their
health through personal support from a pharmacist. The Company stated that
under the new program, a pharmacist contacts enrolled members and work with
them to schedule an in-home visit or a detailed phone consultation, review any
new and/or pre-existing medications, and help the member and their doctor to
create a detailed care plan. Dr. William Fried, Senior Medical Director of the
Company's Southeast Region, stated, "We are very excited to partner with CVS
Caremark and Dovetail Health on this program. By providing a personalized
approach to health care we can help our members stay on track with their
medications, educate them about their treatment, and prevent a repeated trip
to the hospital." The Full Research Report on Aetna Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/cbe9_AET]

--

Illumina Inc. Research Report

On August 19, 2013, Illumina Inc. (Illumina) announced the launch of the new
reagent kits for the MiSeq benchtop sequencer. According to the Company, the
new MiSeq reagents enable up to 15 gigabases (Gb) output, increased number of
sequencing reads up to 25 million and overall read length up to 2x300 base
pairs. The Company further stated that the innovative features of the MiSeq
kits would enable researchers to perform new applications including exome
sequencing on the MiSeq. Christian Henry, Senior Vice President and General
Manager of Illumina's Genomic Solutions business, said, "The new MiSeq kits
are another example of how we are focused on continually improving the
performance and value of our sequencing platforms for our customers. The
latest MiSeq system enhancements deliver the highest data quality and will
open up new applications for researchers in markets as diverse as cancer,
genetic disease, microbiology, agriculture and forensics." The Full Research
Report on Illumina Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/3cf2_ILMN]

--

Pharmacyclics Inc. Research Report

On August 22, 2013, Pharmacyclics Inc. (Pharmacyclics) announced the
publication of a study that investigated ibrutinib's anti-tumor effect in
patients with mantle cell lymphoma (MCL) in a popular journal, Blood. As per
the study, Pharmacyclics' Vice President, Betty Chang, and colleagues, are of
the opinion that the lymphocytes which increase in the peripheral blood during
ibrutinib treatment are MCL cells rather than normal cells. The Company also
stated that the study showed that ibrutinib, an experimental cancer treatment
drug, may directly and potently inhibit MCL cell adhesion and migration in the
residing lymph nodes or tissues. The Full Research Report on Pharmacyclics
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/df74_PCYC]

--

WellCare Health Plans, Inc. Research Report  

On August 21, 2013, WellCare Health Plans, Inc. (WellCare) announced a
contribution of $1 million to the Step Up For Students scholarship program,
which provides scholarships to Florida based students, coming from low-income
families in kindergarten through 12th grade. The Company said that the
scholarships support student's enrollment in private schools or
out-of-district public schools that best fit their needs. The Company's
contribution is likely to provide scholarship support to c.198 during the
2013-2014 school year. Alec Cunningham, WellCare's CEO, said, "WellCare is
committed to helping our members lead better and healthier lives, and to
supporting the communities in which they live. It is an honor to be part of
the Step Up for Students program, and we look forward to continuing our
efforts to build brighter futures for children across Florida." The Full
Research Report on WellCare Health Plans, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/be48_WCG]

--

BioCryst Pharmaceuticals Inc. Research Report

On August 8, 2013, BioCryst Pharmaceuticals Inc. (BioCryst) reported its Q2
2013 financial results. The Company's total revenue declined 80.5% YoY to
$821,000 during the quarter. Net loss was $12.2 million or $0.23 per diluted
share, in Q2 2013, compared to net loss of $12.3 million or $0.25 per diluted
share, in Q2 2012. Additionally, Jon P. Stonehouse, President and CEO of
BioCryst, provided an update on the BCX4161 Phase 1 trial and said, "The fact
that we met all of our goals for the BCX4161 Phase 1 trial and secured
government funding for the peramivir NDA filing represents a significant step
forward for BioCryst. We look forward to initiating the BCX4161 Phase 2a
clinical trial and to submitting a peramivir NDA by year end. Our very
successful recent financing has allowed us to attract additional high quality
investors into the company and has provided us the cash runway to carry us
into 2015." The Full Research Report on BioCryst Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/f9b1_BCRX]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; Phone #: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement